Clinical Trial Matching in China: A Physician's Guide to Oncology Trials
As a treating oncologist, your primary duty is to your patient's safety and the integrity of their care pathway. When standard-of-care options are exhausted, clinical trials offer a vital lifeline. China has evolved into a global powerhouse in oncology research, particularly in CAR-T cell therapy, bispecific antibodies, and targeted therapies for solid tumors (Gastric, HCC, Pancreatic).
Executive Summary: Expanding Your Therapeutic Arsenal, Safely
This page is designed exclusively for physicians. It provides transparent, data-backed insights into how clinical trial matching works in China, the regulatory landscape, the distinction between public and private institutions, and how we ensure seamless, continuous care between the Chinese Principal Investigator (PI) and your practice.
China now accounts for nearly 20-25% of all global oncology clinical trials, up from less than 5% a decade ago. The country is leading the world in novel targets for solid tumors, such as Claudin18.2 (Gastric/Pancreatic) and GPC3 (Hepatocellular Carcinoma), where Western trials have historically struggled.
The Data: Why Consider China for Clinical Trials?
The perception of clinical research in China has shifted dramatically. It is no longer just about patient volume; it is about innovation and speed.
Navigating the Chinese Hospital Landscape
Understanding the critical distinction between public and private institutions for your peace of mind.
| Feature | Public "Grade 3A" (San Jia) Hospitals | Private / International Hospitals |
|---|---|---|
Role in Trials |
The Primary Executors. 95% of Phase I-III oncology trials are run here. | Facilitators/Partners. Cannot run independent Phase I-III trials but often partner with Grade 3A hospitals for patient hospitality and logistics. |
Regulatory Oversight |
Strictly regulated by NMPA (China's FDA) and institutional Ethics Committees. Fully ICH-GCP compliant. | Regulated for clinical practice, but trial data must originate from the partnering Grade 3A institution to be valid. |
Scientific Rigor |
Exceptional. High patient volume allows PIs to see rare mutations and complex cases weekly. | N/A (They refer trial patients to the public partner). |
Communication |
Can be challenging. PIs are highly academic but may have limited English or time for international calls. | Excellent. Dedicated international patient departments with fluent medical translators and 24/7 physician liaisons. |
Examples |
Ruijin Hospital (Shanghai), PUMCH (Beijing), Sun Yat-sen University Cancer Center (Guangzhou). | United Family Healthcare, Jiahui Health (acting as logistical partners for trial patients). |
We exclusively match patients to NMPA-approved, Grade 3A public hospitals for the actual trial execution. We utilize private/international networks only for pre-trial logistics, translation, and post-discharge recovery, ensuring your patient gets the best of both worlds: academic rigor and seamless communication.
The Physician-Centric Matching Workflow
We respect that you are the captain of the ship. We do not bypass you. Our matching process is designed to be an extension of your clinical decision-making.
De-identified Data Submission
You (or our secure portal) submit de-identified patient data: pathology reports, recent imaging (DICOM), molecular profiling (NGS, IHC, Flow Cytometry), and treatment history. Fully HIPAA/GDPR compliant.
15-30 minutes to completeBiomarker & Protocol Cross-Referencing
Our in-house Medical Directors (Board-Certified Oncologists) cross-reference the patient's biomarkers against a live database of 500+ active oncology trials in China.
Within 24 hoursPre-Screening by the Chinese PI
We present the de-identified profile to the Principal Investigator of the shortlisted trials for a preliminary "Soft Yes/No" on eligibility.
24-48 hoursThe Physician Briefing
Before the patient is ever approached, we send you a comprehensive briefing including: Trial Protocol Summary (in English), PI's preliminary assessment, estimated timeline and logistical requirements, and clear delineation of what the sponsor covers vs. out-of-pocket logistics.
48-72 hours totalShared Decision Making
Only after you review and approve do we facilitate an introduction between the patient, your office, and the Chinese trial coordinator. You retain full clinical authority throughout.
Physician-led decisionVisualizing the Advantage
Data-driven comparative analysis of time-to-treatment and cost burden distribution.
Chart A: Time-to-Treatment
Standard of Care vs. Clinical Trial Enrollment (Days)
Chart B: Cost Burden Distribution
International Clinical Trials in China
Investigational drug, protocol-mandated scans, protocol-mandated biopsies, trial-related AE management
Travel, accommodation, standard-of-care procedures not mandated by protocol, pre-existing condition management
Addressing Your Unspoken Concerns
Transparent answers to the questions physicians ask privately.
The NMPA has aggressively aligned its regulations with the ICH-GCP (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use). Furthermore, top-tier Grade 3A hospitals undergo regular, unannounced audits by both the NMPA and international sponsors (including major US/EU pharma companies co-sponsoring these trials).
We only partner with sites that have a proven track record of publishing in high-impact journals (e.g., The Lancet Oncology, JCO).
Patient safety is non-negotiable. The trial protocol mandates immediate SAE reporting. Our medical liaison team ensures that:
- The patient receives immediate, protocol-defined care at the Grade 3A hospital.
- You, the referring physician, are notified via a secure, encrypted channel within 24 hours, including the clinical notes and proposed management plan.
- We facilitate a direct telemedicine bridge between you and the Chinese PI if complex decision-making is required.
No. A core pillar of our service is Continuity of Care. Upon trial completion (or discontinuation), the Chinese PI provides a comprehensive, English-language Discharge Summary and Long-Term Monitoring Plan.
We actively facilitate the handover of care back to your practice, ensuring no gaps in surveillance or subsequent lines of therapy.
Yes, they exist, which is why our vetting is strict. We automatically reject and blacklist any trial that:
- Is not registered on ClinicalTrials.gov or the Chinese Clinical Trial Registry (ChiCTR).
- Lacks formal Ethics Committee (EC) approval.
- Demands upfront "participation fees" from the patient for the investigational drug (a major red flag).
How to Initiate a Match for Your Patient
We know your time is valuable. We have streamlined the referral process to take less than 10 minutes of your staff's time.
Gather Documents
Recent pathology, NGS/IHC reports, and a brief treatment summary.
Secure Upload
Use our encrypted, HIPAA-compliant Physician Portal.
Receive Feedback
Our Medical Director returns a preliminary matching report with 1-3 viable trial options within 48-72 hours.
Questions About Trial Matching?
Our Medical Directors are available to discuss specific cases and trial availability. Contact us directly for a confidential physician-to-physician consultation.
NMPA Grade 3A hospitals • ICH-GCP compliant • HIPAA-aligned • Free for physicians